Oppenheimer upgraded Nektar (NKTR) to Outperform from Perform with a $6 price target Easily identify stocks' risks and opportunities. Discover stocks' market position with detailed competitor ...

Nektar (NKTR) Therapeutics announced a new collaboration agreement to evaluate Nektar’s rezpegaldesleukin in patients with new onset stage 3 type 1 diabetes mellitus. Rezpegaldesleukin is a ...

Yasmeen Rahimi; Analyst; Piper Sandler & Co. Good day and thank you for standing by. Welcome to the Nektar Therapeutics fourth quarter 2024 financial results conference call. (Operator ...

Nektar Therapeutics (NKTR) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of a loss of $0.13 per share. This compares to loss of $0.22 per share a year ago.

SAN FRANCISCO (AP) — SAN FRANCISCO (AP) — Nektar Therapeutics (NKTR) on Wednesday reported fourth-quarter earnings of $7.3 million. The San Francisco-based company said it had net income of 3 ...

Good day, and thank you for standing by. Welcome to the Nektar Therapeutics Fourth Quarter 2024 financial results conference call. At this time, all participants are in a listen-only mode.

(RTTNews) - Below are the earnings highlights for Nektar Therapeutics (NKTR): Earnings: $7.26 million in Q4 vs. -$42.08 million in the same period last year. EPS: $0.03 in Q4 vs. -$0.22 in the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Shares of NKTR stock opened at $0.90 on Thursday. Nektar Therapeutics has a 12 month low of $0.65 and a 12 month high of $1.93. The firm has a market cap of $165.42 million, a PE ratio of -1.07 ...

Nektar Therapeutics (NKTR) reported its Q4 2024 earnings, surpassing analysts’ expectations with an earnings per share (EPS) of $0.03, compared to the forecasted loss of $0.16. The company’s ...

Yasmeen Rahimi; Analyst; Piper Sandler & Co. Good day and thank you for standing by. Welcome to the Nektar Therapeutics fourth quarter 2024 financial results conference call. (Operator Instructions) ...